Yes, I am interested. That said, I don't think there's any rush and I would like to see what Cellceutix' plans are for financing the P2b trials for ABSSSI and P2 for Oral Mucositis.
In Polymedix's Brilacidin (PMX-30063) Antibiotic Fact Sheet, published in February 2013, it was stated "Based on the successful results of this trial, which suggests that shorter courses of therapy and lower doses could be effective, a dose-optimization Phase 2B study is planned. The Phase 2B will study lower doses and shorter courses of therapy." Brilacidin (PMX-30063) Antibiotic Fact Sheet
News 
Market Data 
Discover 
AI
